

February 23, 2017



VolitionRx Limited to Attend the BTIG 2017 Medical Technology, Life Sciences, and Diagnostics Conference

NAMUR, Belgium, Feb. 23, 2017 /PRNewswire/ --[VolitionRx Limited](#) (NYSE MKT: VNRX) today announced that it will attend the BTIG 2017 Medical Technology, Life Sciences, and Diagnostics Conference being held from February 28th - March 3rd, 2017 in Snowbird, UT.

Scott Powell, Executive Vice President of Volition, will provide an update on Volition's business, clinical, regulatory and operational milestones, as well as the Company's recently announced product launch of its Nu.Q™ Colorectal Cancer Screening Triage Test.

Persons attending the conference who would like to schedule a 1-on-1 meeting with Volition management during the conference may do so by contacting Tirth Patel of Edison Advisors at tpatel@edisongroup.com or Scott Powell, Executive Vice President of Volition, at S.Powell@volitionrx.com.

Check out the NEW Corporate Video and Website at www.volitionrx.com

About Volition

Volition is a multi-national life sciences company developing simple, easy to use blood-based cancer tests to accurately diagnose a range of cancers. The tests are based on the science of Nucleosomics®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid -- an indication that disease is present.

As cancer screening programs become more and more widespread, our products can help to diagnose a range of cancers quickly, simply, accurately and cost effectively. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life.

Volition's research and development activities are currently centered in Belgium, with additional offices in London, New York, and Singapore, as the company focuses on bringing its diagnostic products to market first in Europe, then in the U.S. and ultimately, worldwide.

For more information about Volition, visit Volition's website (<http://www.volitionrx.com>) or connect with us via:

Twitter: <https://twitter.com/volitionrx>
LinkedIn: <https://www.linkedin.com/company/volitionrx>
Facebook: <https://www.facebook.com/VolitionRx/>
YouTube: <https://www.youtube.com/user/VolitionRx>

The contents found at Volition's website address, Twitter, LinkedIn, Facebook, and YouTube are not incorporated by reference into this document and should not be considered part of this document. The addresses for Volition's website, Twitter, LinkedIn, Facebook, and YouTube are included in this document as inactive textual references only.

Media / Investor Contacts

Louise Day, Volition
L.day@volitionrx.com
+44 (0)7557 774620

Scott Powell, Volition
S.powell@volitionrx.com
+1 (646) 650 1351

Tirth Patel, Edison Advisors
tpatel@edisongroup.com
+1 (646) 653 7035

Rachel Carroll, Edison Advisors
rcarroll@edisongroup.com
+44 (0)20 3077 5711

Sarah Roberts, Vane Percy & Roberts
sarah@vanepercy.com
+44 (0)1737 821 890

Nucleosomics®, NuQ®, Nu.Q™ and HyperGenomics® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners.

To view the original version on PR Newswire, visit <http://www.prnewswire.com/news-releases/volitionrx-limited-to-attend-the-btfg-2017-medical-technology-life-sciences-and-diagnostics-conference-300412195.html>

SOURCE VolitionRx Ltd.